Stock Analysis, Dividends, Split History

HTGM / HTG Molecular Diagnostics, Inc. financial ratios include Market Cap, Enterprise Value, Book Value, Quick Ratio, Current Ratio, NCAV, EBITDA, Profit Margin, Operating Margin, Return on Invested Capital (ROIC), Return on Assets (ROA), Return on Equity (ROE), Piotroski F-Score, Altman Z-Score, Beneish M Score and Kaplan-Zingales KZ-Index.

Valuation Metrics
Price4.37
Volume364,100.00
Market Cap ($M)130.46
Enterprise Value ($M)124.68
Book Value ($M)27.21
Book Value / Share0.96
Price / Book4.79
NCAV ($M)24.25
NCAV / Share0.85
Price / NCAV5.38
Share Statistics
Common Stock Shares Outstanding 13,929,763
Common Shares Outstanding 28,355,800
Scoring Models
Piotroski F-Score2.00
Altman Z ScoreN/A
Beneish M ScoreN/A
Management Effectiveness (mra)
Return on Invested Capital (ROIC)6.20
Return on Assets (ROA)-1.03
Return on Equity (ROE)3.39
Balance Sheet (mrq) ($M)
Assets49.02
Liabilities21.81
Quick Ratio9.28
Current Ratio9.49
Income Statement (mra) ($M)
Revenues14,759,567.00
Sales Revenue Services Net7,962,312.00
Sales Revenue Goods Net6,797,255.00
Sales Revenue Net14,759,567.00
Operating Income-17.72
Net Income-18.96
Earnings Per Share Basic And Diluted-1.79
Cash Flow Statement (mra) ($M)
Cash From Operations-16.57
Cash from Investing3.28
Cash from Financing-16.57
Identifiers and Descriptors
CUSIP40434H104
Central Index Key (CIK)1169987

Split History

Stock splits are used by HTG Molecular Diagnostics, Inc. to keep share prices within reasonable numbers to encourage investment. If the share price of a security gets too high, a company can perform a stock split by issuing all shareholders an extra share, thereby halving the price of an individual share. If the share price gets too low, companies can do reverse splits. This is common when share prices drop below $1.00 and company's become in danger of being delisted. However, because of the cost, stock splits are not a normal business occurrence.

Coming soon
HTGM : HTG Molecular Diagnostics Stock Analysis and Research Report

2017-10-30 - Asif

HTG Molecular is a commercial stage company that develops and markets products and services based on proprietary technology that facilitates the routine use of targeted molecular profiling. Molecular profiling is the collection of information about multiple molecular targets, such as DNA and RNA, also called biomarkers, in a biological sample. Molecular profiling information has many important applications, from basic research to molecular diagnostics in personalized medicine. Its technology can be used throughout that range of applications, which is just one of its many benefits. Its focus is on clinical applications. Its primary customer segments include biopharmaceutical companies, academic research centers and molecular testing laboratories. Historically, molecular profiling has faced several technical challenges in clinical applications. These include (i) limited “multiplexing,” which means only a few biomarkers could be tested in a single sample; (ii) the need for vast amount...

Related News Stories

HTG Molecular Diagnostics, Inc. (HTGM) CEO T. J. Johnson on Q2 2018 Results - Earnings Call Transcript

2018-08-12 seekingalpha
HTG Molecular Diagnostics, Inc (NASDAQ:HTGM) Q2 2018 Earnings Conference Call August 7, 2018 4:30 PM ET

HTG Molecular Diagnostics, Inc. (HTGM) Reports Q2 Loss, Lags Revenue Estimates

2018-08-08 zacks
HTG Molecular Diagnostics, Inc. (HTGM - Free Report) just came out with a quarterly loss of $0.14 per share versus the Zacks Consensus Estimate of a loss of $0.19. This compares to loss of $0.60 per share a year ago. These figures are adjusted for non-recurring items. (1-2)

HTG Molecular: Entering Stage Of Growth And Momentum

2018-06-11 seekingalpha
HTGM develops next generation sequencing (NGS) tools utilized by physicians and patients to create a patient-specific course of treatment. (29-4)

The Eleven: Viking Skyrockets, Global Blood Is Fueling

2018-06-04 seekingalpha
The Eleven is a biotechnology portfolio of eleven stocks we believe have significant upside within a six month to one-year timeframe based upon company fundamentals and upcoming catalysts with good risk/reward ratios. They are listed in a way to reflect top picks and risk tolerance. The first five picks are the top picks (in no particular order). Risks are increased the further away a stock sits from the middle (Picks #6, in the middle of the list, is the least risky). (96-9)

HTG Molecular Diagnostics' (HTGM) CEO T. J. Johnson on Q1 2018 Results - Earnings Call Transcript

2018-05-11 seekingalpha
Good day, and welcome to the HTG Molecular Diagnostics' First Quarter 2018 Earnings Conference Call. Today's conference is being recorded. (29-1)

2 Attractive Biotechs Under $5

2018-04-23 seekingalpha
Today we cover two attractive healthcare plays whose stocks happen to be currently selling under $5 a share. (48-4)

BRIEF-HTG Molecular Diagnostics Inc Says On March 30, 2018, Co And Qiagen Manchester Limited Entered Second Amendment Of First Statement Of Work

2018-04-04 reuters
* HTG MOLECULAR DIAGNOSTICS INC - ON MARCH 30, 2018, CO AND QIAGEN MANCHESTER LIMITED ENTERED SECOND AMENDMENT OF FIRST STATEMENT OF WORK - SEC FILING (29-2)

BRIEF-Htg Molecular Diagnostics Secures Debt Facility With Midcap Financial

2018-03-27 reuters
* HTG MOLECULAR DIAGNOSTICS INC - ENTERED INTO A SENIOR DEBT FACILITY WITH MIDCAP FINANCIAL TO REPLACE ITS EXISTING SENIOR CREDIT FACILITY (29-1)

CUSIP: 40434H104